Cargando…
Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection
BACKGROUND: Clostridium difficile infection (CDI), a complication of antibiotic-induced injury to the gut microbiome, is a prevalent and dangerous cause of infectious diarrhea. Antimicrobial therapy for CDI is typically effective for acute symptoms, but up to one third of patients later experience r...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506624/ https://www.ncbi.nlm.nih.gov/pubmed/25885020 http://dx.doi.org/10.1186/s12879-015-0930-z |
_version_ | 1782381723158315008 |
---|---|
author | Hirsch, Bruce E Saraiya, Nimit Poeth, Kaitlin Schwartz, Rebecca M Epstein, Marcia E Honig, Gerard |
author_facet | Hirsch, Bruce E Saraiya, Nimit Poeth, Kaitlin Schwartz, Rebecca M Epstein, Marcia E Honig, Gerard |
author_sort | Hirsch, Bruce E |
collection | PubMed |
description | BACKGROUND: Clostridium difficile infection (CDI), a complication of antibiotic-induced injury to the gut microbiome, is a prevalent and dangerous cause of infectious diarrhea. Antimicrobial therapy for CDI is typically effective for acute symptoms, but up to one third of patients later experience recurrent CDI. Fecal-derived microbiota transplantation (FMT) can ameliorate the underlying dysbiosis and is highly effective for recurrent CDI. Traditional methods of FMT are limited by patient discomfort, risk and inefficient procedures. Many individuals with recurrent CDI have extensive comorbidities and advanced age. Widespread use of FMT requires strategies that are non-invasive, scalable and applicable across healthcare settings. METHODS: A method to facilitate microbiota transfer was developed. Fecal samples were collected and screened for potential pathogens. Bacteria were purified, concentrated, cryopreserved and formulated into multi-layered capsules. Capsules were administered to patients with recurrent CDI, who were then monitored for 90 days. RESULTS: Thirteen women and six men with recurrent CDI were provided with microbiota transfer with orally administered capsules. The procedure was well tolerated. Thirteen individuals responded to a single course. Four patients were cured after a second course. There were 2 failures. The cumulative clinical cure rate of 89% is similar to the rates achieved with reported fecal-derived transplantation procedures. CONCLUSIONS: Recurrent CDI represents a profound dysbiosis and a debilitating chronic disease. Stable cure can be achieved by restoring the gut microbiome with an effective, well-tolerated oral capsule treatment. This strategy of microbiota transfer can be widely applied and is particularly appropriate for frail patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-0930-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4506624 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45066242015-07-19 Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection Hirsch, Bruce E Saraiya, Nimit Poeth, Kaitlin Schwartz, Rebecca M Epstein, Marcia E Honig, Gerard BMC Infect Dis Research Article BACKGROUND: Clostridium difficile infection (CDI), a complication of antibiotic-induced injury to the gut microbiome, is a prevalent and dangerous cause of infectious diarrhea. Antimicrobial therapy for CDI is typically effective for acute symptoms, but up to one third of patients later experience recurrent CDI. Fecal-derived microbiota transplantation (FMT) can ameliorate the underlying dysbiosis and is highly effective for recurrent CDI. Traditional methods of FMT are limited by patient discomfort, risk and inefficient procedures. Many individuals with recurrent CDI have extensive comorbidities and advanced age. Widespread use of FMT requires strategies that are non-invasive, scalable and applicable across healthcare settings. METHODS: A method to facilitate microbiota transfer was developed. Fecal samples were collected and screened for potential pathogens. Bacteria were purified, concentrated, cryopreserved and formulated into multi-layered capsules. Capsules were administered to patients with recurrent CDI, who were then monitored for 90 days. RESULTS: Thirteen women and six men with recurrent CDI were provided with microbiota transfer with orally administered capsules. The procedure was well tolerated. Thirteen individuals responded to a single course. Four patients were cured after a second course. There were 2 failures. The cumulative clinical cure rate of 89% is similar to the rates achieved with reported fecal-derived transplantation procedures. CONCLUSIONS: Recurrent CDI represents a profound dysbiosis and a debilitating chronic disease. Stable cure can be achieved by restoring the gut microbiome with an effective, well-tolerated oral capsule treatment. This strategy of microbiota transfer can be widely applied and is particularly appropriate for frail patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-0930-z) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-17 /pmc/articles/PMC4506624/ /pubmed/25885020 http://dx.doi.org/10.1186/s12879-015-0930-z Text en © Hirsch et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Hirsch, Bruce E Saraiya, Nimit Poeth, Kaitlin Schwartz, Rebecca M Epstein, Marcia E Honig, Gerard Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection |
title | Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection |
title_full | Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection |
title_fullStr | Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection |
title_full_unstemmed | Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection |
title_short | Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection |
title_sort | effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent clostridium difficile infection |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506624/ https://www.ncbi.nlm.nih.gov/pubmed/25885020 http://dx.doi.org/10.1186/s12879-015-0930-z |
work_keys_str_mv | AT hirschbrucee effectivenessoffecalderivedmicrobiotatransferusingorallyadministeredcapsulesforrecurrentclostridiumdifficileinfection AT saraiyanimit effectivenessoffecalderivedmicrobiotatransferusingorallyadministeredcapsulesforrecurrentclostridiumdifficileinfection AT poethkaitlin effectivenessoffecalderivedmicrobiotatransferusingorallyadministeredcapsulesforrecurrentclostridiumdifficileinfection AT schwartzrebeccam effectivenessoffecalderivedmicrobiotatransferusingorallyadministeredcapsulesforrecurrentclostridiumdifficileinfection AT epsteinmarciae effectivenessoffecalderivedmicrobiotatransferusingorallyadministeredcapsulesforrecurrentclostridiumdifficileinfection AT honiggerard effectivenessoffecalderivedmicrobiotatransferusingorallyadministeredcapsulesforrecurrentclostridiumdifficileinfection |